Around 6% of primary cancer cases are estimated to be affected by HR deficiency (17), and identifying these cases is of substantial importance for treatment, because HR-deficient cancers show greatly increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based cross-linking agents (18). Here, PARP1 is linked to cancer.